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ABSTRACT
pH is a ubiquitous regulator of biological activity, including protein-folding, protein-protein interactions, and enzymatic
activity. Existing constant pH molecular dynamics (CPHMD) models that were developed to address questions related to the
pH-dependent properties of proteins are largely based on implicit solvent models. However, implicit solvent models are
known to underestimate the desolvation energy of buried charged residues, increasing the error associated with predictions
that involve internal ionizable residue that are important in processes like hydrogen transport and electron transfer. Fur-
thermore, discrete water and ions cannot be modeled in implicit solvent, which are important in systems like membrane
proteins and ion channels. We report on an explicit solvent constant pH molecular dynamics framework based on multi-site
k-dynamics (CPHMDMSkD). In the CPHMDMSkD framework, we performed seamless alchemical transitions between protona-
tion and tautomeric states using multi-site k-dynamics, and designed novel biasing potentials to ensure that the physical
end-states are predominantly sampled. We show that explicit solvent CPHMDMSkD simulations model realistic pH-
dependent properties of proteins such as the Hen-Egg White Lysozyme (HEWL), binding domain of 2-oxoglutarate dehydro-
genase (BBL) and N-terminal domain of ribosomal protein L9 (NTL9), and the pKa predictions are in excellent agreement
with experimental values, with a RMSE ranging from 0.72 to 0.84 pKa units. With the recent development of the explicit sol-
vent CPHMDMSkD framework for nucleic acids, accurate modeling of pH-dependent properties of both major class of bio-
molecules—proteins and nucleic acids is now possible.
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INTRODUCTION
pH is one of the critical regulators of biological activity.
Enzymatic activity is optimized within a narrow pH
range,1 often requiring the participation or presence of
ionizable residues such as aspartic acid, glutamic acid and/
or histidine in the active site,2 and accurate measurement
of their pKa values is crucial in understanding the catalytic
mechanism.3–5 In recent years, the role of pH regulation
in nucleic acid systems has been acknowledged,6,7 where
parallels to proteins can be drawn, such as the catalytic
activity of ribozymes (ribonucleic acid enzyme),8–11 dem-
onstrating the ubiquity of pH regulation in biological
processes. Apart from its influence on catalytic activity, pH
regulation has been observed in numerous other processes
including protein folding,12–15 protein-protein interac-
tions,16 protein-substrate binding,17,18 translational
recoding,19 and aberrant pH regulation has even been
implicated in cancer-related physiology.20 As such, specific
examples of pH-dependent properties encompass a wide
variety of systems, such as the catalytic mechanism of
dihydrofolate reductase,21 proton gradient driven ATP
synthesis,22 activity of the U6 intramolecular stem-loop of
the spliceosome complex23 and the influenza virus
haemagglutinin.24
While the pKa values of amino acid monomers have
been known for decades, the microenvironment around
the residue located in a protein environment may alter
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its pKa value. Thus, the ability to measure the micro-
scopic pKa of a site-specific residue is invaluable in iden-
tifying key titrating residues and understanding the
mechanism of these pH-dependent biological processes.
Using staphylococcal nuclease and its mutants as a model
system, Garcia-Moreno and co-workers undertook a
series of comprehensive investigations into the effect that
the local microenvironment has on the perturbation of
the pKa values of protein residues.25–28 Their effort has
cumulated in a joint collaboration between experimental-
ists and theoreticians, where the current state-of-the-art
computational methods for predicting protein pKa values
were evaluated against experimentally measured pKa
values.29,30
One major physics-based approach that has emerged
over the years to treat electrostatics in proteins and
nucleic acids is the Poisson-Boltzmann (PB) equation
methodology, which has achieved reasonable success in
predicting protein pKa values.31 A key limitation of ini-
tial PB methods was the lack of conformational flexibil-
ity, although this has been partially addressed using
approaches like tuning the effective protein dielectric
constant32 and including representations of multiple
conformations.33,34 The need for conformational flexi-
bility led to the development of the other major physics-
based approach in computational pKa predictions, which
is based on molecular dynamics (MD) simulation. War-
shel and co-workers were the first to demonstrate the use
of free energy calculations to calculate the pKa values of
protein residues.35–38 Subsequent developments in the
MD community have sought to couple the protonation
state of the titrating residue with the dynamics of the
protein itself. Such pH-coupled simulations, which have
been termed constant pH molecular dynamics
(CPHMD), are uniquely suited to model realistic pH-
dependent responses, even in systems where there is lim-
ited experimental data because no a priori information
on the identity of key titrating residues and their proto-
nation state is required.
The CPHMD methodology has been implemented
using two distinct approaches, which vary in the manner
in which the titration coordinates are treated—either dis-
cretely or continuously.39 In the discrete CPHMD vari-
ant, the MD sampling of atomic coordinates is combined
with the Monte Carlo (MC) sampling of protonation
states. At regular intervals during a typical MD simula-
tion, a MC step is performed to determine the change of
the protonation state. Discrete CPHMD was first reported
by Burgi et al.,40 which was computationally expensive at
that time and suffered from convergence issues, owing to
the fact that it was performed in explicit solvent and used
the more expensive thermodynamic integration approach
to calculate the energies used in the MC evaluation step.
Baptista et al. reported a similar discrete CPHMD imple-
mentation but used the Poisson-Boltzmann finite-differ-
ence method to calculate the energies used in the MC
evaluation step.41–43 With the advances in implicit solva-
tion models around this time,44,45 and the initial conver-
gence issues reported for explicit solvent CPHMD,40
subsequent developments in discrete CPHMD by Dlugosz
and Antosiewicz,46,47 and Mongan et al.,48 were imple-
mented using a Generalized-Born (GB) implicit solvent
model. More recent improvements in the discrete
CPHMD community have been focused on achieving bet-
ter sampling by enhanced sampling techniques, such as
Accelerated Molecular Dynamics by Williams et al.49 and
replica exchange strategies by Roitberg and co-work-
ers.50–52 Others in the field, namely Messer et al. have
focused on developing a more physically realistic form of
CPHMD,53 using time-dependent MC sampling of the
proton transfer process,54 and the empirical valence bond
(EVB) framework to simulate proton transfer between
solute and solvent.55
By contrast, in the continuous CPHMD variant, which
were first reported by Baptista et al.56 and Borjesson et.
al.,57 titration coordinates can be treated as mixed states.
In the continuous CPHMD variant developed by Brooks
and co-workers, the titration coordinate represents an
instantaneous microstate, and it is propagated continu-
ously between the protonated and unprotonated states
using the k dynamics approach.58–60 Continuous
CPHMD allows one to avoid sudden jumps in potential
energy that occur after a successful MC move in the dis-
crete CPHMD variant, and potentially avoids artifacts
that may be caused by the MC moves in titration coordi-
nates. Additionally, continuous CPHMD facilitates
coupled proton moves, which would need to be engi-
neered as specific move types in the MC-based variant.
Continuous CPHMD was originally implemented in
implicit solvent,61 improved to account for proton tau-
tomerism,62 and it provided the first demonstration of
using enhanced sampling strategies to accelerate sampling
and convergence in CPHMD simulations.63 The effec-
tiveness of continuous CPHMD has been demonstrated
on numerous pH-dependent systems, inclusive of protein
folding,64,65 aggregation of Alzheimer’s beta-amyloid
peptides,66 pH-triggered chaperon activity of HdeA
dimers,67 electrostatic effects on protein stability,68 self-
assembly of spider silk proteins,69 and RNA silencing in
the carnation italian ringspot virus.70 Other investigators
in the field have also seen a number of successes using
discrete CPHMD simulations.71–73
While the move to implicit solvent CPHMD has
obvious advantages in sampling and convergence, a
number of unresolved issues have emerged over the
years. It has been reported that the generalized Born
implicit solvent model underestimates the desolvation of
buried charge-charge interactions,63 causing a systematic
overstabilization of the ionized form74 and consequently
increasing the error of predicted pKa values. In addition,
these models are known to cause structural compaction
which may distort the overall structure,68,75 introducing
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another source of error to the pKa calculations. Further-
more, in systems such as ion channels76–78 and some
transmembrane proteins,79 where the microscopic inter-
actions of discrete ions and water with the protein are
important, the use of an explicit solvent representation
of the solvent environment is desirable. Thus, recent
developments in the continuous CPHMD community
have been focused on re-introducing explicit solvent into
the CPHMD framework. Wallace and Shen were the first
to report a hybrid solvent CPHMD model, and showed
that using an explicit solvent representation of the pro-
tein’s conformational dynamics can reduce the errors
introduced by the GB implicit model.75 Around the
same time, the first “pure” explicit solvent CPHMD was
reported by Donnini et al., with a proof of concept dem-
onstration for model amino acid compounds.80 Brooks
and co-workers subsequently reported another “pure”
explicit solvent constant pH MD simulation, termed as
CPHMDMSkD as it is based on the newer multi-site k-
dynamics (MSkD) framework.81,82 CPHMDMSkD was
developed initially for investigating pH-dependent behav-
ior of nucleic acid systems and it has been validated on
both model nucleotides83 and larger RNA systems.84
The initial challenges associated with convergence in
explicit solvent were noted by practitioners in the
field,80,83 and have been addressed to some extent using
enhanced sampling strategies.75,85 More recent develop-
ments in enhanced sampling methods, such as Orthogo-
nal Space Random Walk by Zheng et al. have
demonstrated that accurate pKa calculations for buried
protein residues in explicit solvent simulations can be
achieved,86 indicating that practical challenges first
encountered by Burgi et al. over a decade ago will be
resolved eventually.
In this article, we will adopt the explicit solvent
CPHMDMSkD framework and extend its application to
include proteins. We apply the multi-site k-dynamics
(MSkD) algorithm to seamlessly perform alchemical reac-
tions between protonation and tautomeric states, and
develop a novel biasing potential to ensure that the physi-
cal end-states are adequately sampled. The quality of the
CPHMDMSkD model for proteins will be demonstrated by
its ability to reproduce the pKa values of model com-
pounds, simulate coupled pH-dependent behavior of
dipeptides, and to accurately reproduce experimental pKa
values of proteins, such as the hen egg-white lysozyme
(HEWL), the binding domain of 2-oxoglutarate dehydro-
genase (BBL) and the N-terminal of ribosomal protein L9
(NTL9).
THEORY
Constant pH molecular dynamics
simulations in explicit solvent
We briefly review the theory behind constant
pH molecular dynamics (CPHMD). In CPHMD, the
protonation state of the titrating residue is described by
a continuous variable, k. The dynamics of k is described
according to multi-site k-dynamics (MSkD),81,82 a for-
malism that couples the dynamics of k to the dynamics
of the protein system. The simulation is under the influ-
ence of a hybrid Hamiltonian and its potential energy is
described by:
UtotðX ; fxg; fkgÞ5UenvðXÞ1
XNsites
a51
½ka;1ðUðX; xa;1ÞÞ
1ka;2ðUðX ; xa;2ÞÞ
(1)
where Nsites is the total number of titrating residues, X
represents the coordinates of the environment atoms
(i.e., the parts of the protein that are not titrating), and
xa,1 and xa,2 represent the coordinates of atoms in resi-
due a that are associated with the protonated and
unprotonated states, respectively. k serves as a scaling
factor that is associated with each titrating residue a and
its value describes the physically relevant protonated
(ka,15 1) and unprotonated (ka,25 1) states. Details
about the theoretical and methodological treatment of k
dynamics can be found in the following references.81,82
CPHMD simulations are calibrated on model com-
pounds (i.e., amino acids) to reproduce the external pH
environment. Modeling of the external pH is achieved by
introducing a fixed biasing potential parameter (Ffixeda;2 )
to the unprotonated state, which results in the biased
potential energy function:
UtotðX ; fxg; fkgÞ5UenvðXÞ1
XNsites
a51
½ka;1ðUðX; xa;1ÞÞ
1ka;2ðUðX ; xa;2Þ2F f ixeda;2 Þ
(2)
The free energy of protonation (DG protonation ) is used
to calibrate the biasing potential (F fixeda;2 ) that simulates
the effect of an external pH environment. By setting the
value of F fixeda;2 to DG protonation , approximately equal pop-
ulations of protonated and unprotonated states are
sampled in the simulation. Under this condition, the
external pH environment is equal to the pKa value of the
model compound. To change the pH of the simulation,
F fixeda;2 can be adjusted by the following equation:
F f ixeda;2 5DG protonation1ln ð10ÞkBTðpK a2pH Þ; (3)
where pH is the external pH of the simulation and pKa
is the experimental pKa of the model compound. The
fixed biasing potential is pre-calculated and its value,
corresponding to the specified external pH, is universally
applied to all residues of the same type regardless of the
protein environment it is in. In explicit solvent CPHMD
simulations, when the titration coordinates are allowed
to propagate dynamically, the two end points that
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correspond to physical protonation states may not be
sufficiently sampled to yield converged estimates of the
pKa shifts. To ameliorate this issue, the inclusion of an
extra variable biasing potential (Fvar) is introduced,
which can be adjusted to tune the sampling efficiency of
titration coordinates and the fraction of physical proto-
nation states:
Fvara;i 5
kbias ka;i20:8
 2
; if ki < 0:8
0; otherwise
(
(4)
Thus, in the CPHMD treatment, titratable groups in
proteins may be viewed as model compounds that are
perturbed by the introduction of the protein environ-
ment. Further details on the implementation and calibra-
tion of explicit solvent CPHMDMSkD can be obtained
from the following reference.83
pH replica exchange sampling protocol
The potential for slow convergence of protonation
state sampling in CPHMD simulations has been well
documented, and is exacerbated for residues with
conformationally-coupled pKa values, where they
undergo a local conformation change that causes them
to sample different electrostatic environments yielding
distinct microscopic pKa values.49,84,87 Early work by
Khandogin and Brooks on protein CPHMD simulations
has demonstrated that the introduction of a temperature
replica exchange (T-REX) protocol can significantly
accelerate sampling to address such issues.63 However,
using T-REX in explicit solvent MD simulations typically
incurs a large computational expense, for example, a
moderate sized protein of 100 residues (40k atoms
when solvated) requires at least 20 replicas to achieve
reasonable exchange rates between adjacent temperature
replicas, and when simulating CPHMD across a reasona-
ble pH range (e.g., pH 5 to 9), the total number of repli-
cas required increases to 100. Therefore, in this paper,
we used a pH replica exchange (pH-REX) sampling strat-
egy instead, and the pH-REX sampling protocol imple-
mented in our work is based on the work of Wallace and
Shen,75 where simulations performed at various pH con-
ditions are exchanged based on the following Metropolis
criterion:
P5
1; if D  0
expð2DÞ; otherwise
where D5b
U pH ðfkig; pH0Þ1U pH ðfki 0g; pH Þ
2UpH ðfkig; pH Þ2U pH ðfki 0g; pH0Þ
2
4
3
5
8<
: (5)
where b is 1/kbT, the first two terms, U pH ðfkig; pH0Þ
and U pH ðfki 0g; pH Þ are the pH-biasing potential ener-
gies for the two adjacent replicas after the exchange, and
the next two terms, U pH ðfkig; pH Þ and U pH ki 0f g;ð
pH’Þare the corresponding energies for the respective
replicas before the exchange.
METHODS
Generating input structures
Input structures of the peptide compounds were gen-
erated from the CHARMM topology files using the IC
facility in CHARMM.88 The input structure for the pro-
tein hen egg-white lysozyme (HEWL), the 45-residue
binding domain of 2-oxoglutarate dehydrogenase multi-
enzyme complex (BBL) and the 56-residue N-terminal
domain of ribosomal protein L9 (NTL9) were generated
from the PDB file (accession codes: 2LZT, 1W4H, 1CQU,
respectively). Hydrogen atoms were added using the
HBUILD facility in CHARMM. Model compounds (sin-
gle amino acids), test compounds (dipeptide sequences)
and the proteins were solvated in a cubic box of explicit
TIP3P water89 using the convpdb.pl tool from the
MMTSB toolset.90 For each protein, the system was first
neutralized, before an appropriate number of Na1 and
Cl2 counterions was added to match the experimental
ionic strength of 100 mM NaCl. All systems were capped
at the N-terminus and C-terminus using CHARMM’s
ACE and CT2 patches. Additional patches were con-
structed to represent the protonated forms of Asp, Glu,
His, and Lys. All of the associated bonds, angles and
dihedrals were explicitly defined in the patch. Each titrat-
able residue was simulated as a hybrid model that explic-
itly included atomic components of both the protonated
and unprotonated forms. The CHARMM parameters for
the partial charges of aspartic acid, glutamic acid and
lysine used in this study were reported previously by Lee
et al.61 Partial charges for the three protonation states of
histidine were obtained without modification from the
HSP, HSE and HSD residues as reported in the
CHARM22 all-atom force field for proteins.91
Simulation details
MD simulations were performed within the CHARMM
macromolecular modeling program (version c36a6) using
the CHARMM22 all-atom force field for proteins91 and
TIP3P water.89 The SHAKE algorithm92 was used to con-
strain the hydrogen-heavy atom bond lengths. The
G.B. Goh et al.
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Leapfrog Verlet integrator was used with an integration
time step of 2 fs. A non-bonded cutoff of 12 A˚ was used
with an electrostatic force shifting function and a van der
Waals switching function. While group-based 8 A˚ cutoffs
investigated in the 1990s were notoriously poor in repro-
ducing accurate dynamics of biomolecules relative to the
Ewald summation technique,93,94 modern atom-based
cutoff schemes with sufficiently long cutoff distances (12
A˚),95 such as those employed in this study, has been
shown to be comparable to the Ewald summation tech-
nique in modeling the dynamics of both proteins96 and
nucleic acids.97 Titration was performed in the multi-site
k-dynamics framework (MSkD)81,82 within the BLOCK
facility, using the kNexp functional form for k (FNEX) with
a coefficient of 5.5.81,82 The titratable fragment included
the protonation site and adjacent atoms whose partial
charge differed according to the protonation state. The
environment atoms were defined as all atoms that were
not included in the titratable fragments. Linear scaling by
k was applied to all energy terms except bond, angle and
dihedral terms, which were treated at full strength regard-
less of k value to retain physically reasonable geometries.
Each ha was assigned a fictitious mass of 12 amu•A˚
2 and k
values were saved every 10 steps. The temperature was
maintained at 298K by coupling to a Langevin heatbath
using a frictional coefficient of 10 ps21. After an initial
minimization, the system was heated for 100 ps and equili-
brated for 100 ps (for amino acid compounds and dipepti-
des) or 400 ps (for HEWL, BBL, and NTL9). This was
followed by a production run of 3 ns (for amino acid com-
pounds, dipeptides and NTL9), 5 ns (for BBL), or 20 ns
(for HEWL). CPHMDMSkD simulations were performed
across the pH range, with integer value pH spacing, as
indicated in the titration curves (see Results and Discus-
sion), from pH 1 to 7 for Asp and Glu, pH 4 to 9 for His,
pH 7 to 12 for Lys, pH 0 to 8 for HEWL, and pH 0 to 5 for
BBL and NTL9. In the pH-REX simulations, exchange
attempts were made at every 1 ps. All CPHMDMSkD simu-
lations were performed in triplicate.
Calculation of pKa value
The populations of unprotonated (Nunprot) and proto-
nated (Nprot) states are defined as the total number of
times in the trajectory where conditions ka,1> 0.8 and
ka,2> 0.8 are satisfied respectively. They are used in the
calculation of the fraction of physical states, which is the
ratio of Nunprot and Nprot states over all states (which
include intermediate k values). The unprotonated frac-
tion (Sunprot) is calculated for each pH window:
Sunprot pHð Þ5 N
unprot pHð Þ
Nunprot pHð Þ1Nprot pHð Þ (6)
Sunprot values computed across the entire pH range,
were then fitted to a generalized version of the
Henderson-Hasselbalch (HH) formula98 to obtain a sin-
gle pKa value:
Sunprot pHð Þ5 1
11102nðpH2pKaÞ
(7)
To illustrate the effect of coupled titrating residues,
CPHMDMSkD simulations on several dipeptides (see Sup-
porting Information for discussion) were also performed.
For these dipeptide simulations, the protonation state
statistics for a specific residue may not be associated
with the titrating residue, because the symmetry of the
system may render the environment around each titrat-
ing residue to be similar. Therefore, the pKa calculation
has to be performed using a modified version of Eq. (7),
where the combined Sunprot ratio for all i residues is fit-
ted to the following equation:
XN
i
S
unprot
i pHð Þ5
XN
i
1
11102ðpH2pKaiÞ
(8)
In this study, the reported pKa value and its uncer-
tainty correspond to the mean and standard deviation
calculated from three sets of independent runs.
RESULTS & DISCUSSION
Optimization of model potential parameters
for two-state titrations
As with the previous implementation of CPHMDMSkD
for nucleic acids,83 we used the free energy of deproto-
nation as the fixed biasing potential (Ffixed) in our simu-
lation. The free energy of deprotonation was calculated
for each isolated model compound embedded in explicit
solvent using traditional k-dynamics at zero ionic
strength. In order to facilitate transitions between the
two protonation states, we optimized the force constant
(kbias) on the variable biasing potential (F
var) that was
applied to each model compound, and targeted to
achieve a maximal value of the transition rate in k-space
(i.e., titration coordinate sampling), while maintaining a
high fraction of physical ligands. The optimized parame-
ters for the model potentials are reported in Table I. Cal-
culation of the sampling statistics (see Supporting
Information Table S1) indicates that the fraction of phys-
ical states was maintained at 70% and transitions in k-
space were 50 transitions/ns. The sampling properties
of our model amino acids are comparable to previous
work performed on model nucleosides in explicit
solvent.83
Next, we performed a two-state titration simulation,
where only two titrating states (protonated and unproto-
nated) were simulated, and tautomers for each protona-
tion state were not explicitly modeled. The titration
curves for our model compounds are illustrated in Figure
Explicit Solvent CPHMD of Proteins
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1. The calculated pKa of aspartic and glutamic acid for a
two-state titration (i.e., without proton tautomerism) was
4.1 and 4.3 pKa respectively, which is within 60.1 pKa
units from their experimental pKa values of 4.0 and 4.4
respectively.99 For the two-state titration of histidine,
where either Nd or NE was titrated, the pKa values
obtained were 6.7 and 7.0 respectively,100 which is identi-
cal to their experimental pKa values. Finally, the calculated
pKa of lysine was 10.2, which is in close agreement with
the experimental pKa value of 10.4.
99 The excellent agree-
ment between our model compounds calculated pKa val-
ues and their experimental values indicate that the
sampling of titration coordinates in our CPHMDMSkD
simulations was sufficient to yield accurate results.
Optimization of model potential parameters
for three-state titrations
The original form of the Fvar potential assumed the
existence of only two states. When accounting for proton
tautomerism and thus three states, the original form was
not suitable because it frequently sampled an intermedi-
ate state of the two tautomers. This intermediate state is
typically characterized by ka,1  0, ka,2  0.5 and ka,3 
0.5, which corresponds to a half proton on both the Nd
and Ne protonation sites (using His as an example), and
this represents an unphysical state whose sampling
should be minimized. The existence of the intermediate
state can be rationalized by considering that the free
energy barrier for conversion between the two protona-
tion states would be larger than the conversion between
the two tautomers, as in the former process there is a
change in the net charge of the system and a greater
reorganization of the distribution of partial charges. The
combined functional form of the original Fvar potential
that uses the same 0.8 cutoff in the definition of physical
protonation states (see Methods section) as expressed in
Eq. (9), where ka,1, ka,2 and ka,3 denote the alchemical
scaling factors associated with each of the three states for
some residue a, does not account for the uneven barrier
height of the different alchemical reactions.
Fvara 5k1 ka;120:8
 2
1k1 ka;220:8
 2
1k1 ka;320:8
 2
(9)
To avoid the intermediate tautomeric states, we modi-
fied the existing Fvar potential by including additional
cross terms (k2 expressions) to account for uneven bar-
rier heights, and a final term (k3 expressions) was added
to ensure that the relative free energy of the end-states
were not altered. The resulting functional form as out-
lined in Eq. (10) results in a more versatile biasing
potential that is suited to address the asymmetry of the
potential energy surface associated with changes in both
protonation and tautomeric states.
Table I
Parameters for the Model Potential for Two-State Titrations
Residue DGprotonation (kcal/mol)
Fvar (kcal/mol)
kbias Ref pKa
Asp 43.71 34.00 4.00
Glu 46.00 34.25 4.40
His-d 23.58 26.00 7.00
His-E 212.26 26.00 6.60
Lys 223.02 29.50 10.40
Figure 1
Titration curve of model compounds: (a) aspartic acid, (b) glutamic acid, (c) lysine, (d) histidine-d, and (e) histidine-e. Calculated pKa values of
model compounds are in excellent agreement with experimental pKa values. Colors represent the results from the triplicate runs.
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Fvara 5k1 ka;120:8
 2
1k1 ka;220:8
 2
1k1 ka;320:8
 2
1k2 ka;12ka;2
 2
k2 ka;12ka;3
 2
2k3 ka;2
 
2k3 ka;3
 
(10)
An iterative grid search strategy was used in testing
various combinations of the force constants (k1, k2, k3),
and the optimal combination is reported in Table II. As
illustrated in Figure 2, which shows the time-evolution
of k, all three end states for the model compounds were
well sampled. Calculation of the sampling statistics as
summarized in Table III indicates that the fraction of
physical states was maintained above 70%, confirming
that the modified Fvar potential does not trap k in an
unphysical intermediate state. The transitions in k-space
were 50 transitions/ns, which is comparable to the sta-
tistics obtained from two-state titrations of the model
compounds.
While the sampling efficiency in k-space of model
compounds allows us to reproduce the pKa values of the
model compounds, the transition rate is nevertheless
limited to 50 transitions/ns. In our previous evaluation
of explicit solvent CPHMDMSkD simulations of larger
nucleic acid structures, slower pKa convergence was
observed,84 and it is likely that protein systems
will encounter similar issues as well. The sampling of
titration and spatial coordinates can be accelerated using
a pH-REX sampling strategy.85 Therefore, we have
applied pH-REX sampling, and as illustrated in Table III,
it resulted in a sixfold improvement in k-space sampling
of model compounds with effectively no loss in the frac-
tion of physical states. As pH-REX sampling confers sig-
nificant improvement over straightforward MD
simulations and requires negligible overhead in terms of
computational cost, the results presented in the subse-
quent sections are obtained from pH-REX CPHMDMSkD
simulations unless specified otherwise.
We performed a three-state titration on the model
compounds, where alchemical transformations across dif-
ferent protonation states and across different tautomers
of the same protonation state were explicitly modeled.
The tautomeric titrations of aspartic and glutamic
yielded a pKa of 4.4 and 4.8 respectively, which matches
well with the macroscopic pKa of 4.35 and 4.70 when the
double degeneracy of the protonated states is taken into
account.62 However, since the experimental pKa meas-
ured does not distinguish between the tautomeric forms,
we recalibrated the fixed biasing potential in our
CPHMDMSkD simulations to reproduce the experimen-
tally measured macroscopic pKa values. This was
Table II
Parameters for the Model Potential for Three-State Titrations
Fvar (kcal/mol)
Residue DGprotonation (kcal/mol) k1 k2 k3 Ref. pKa
Asp-T 43.30 216.5 18.5 218.5 4.00
Glu-T 45.59 216.0 18.5 218.5 4.40
His-T 23.58/212.26 8.0 6.0 26.0 6.45
Figure 2
Titration coordinate transitions of aspartic acid at pH 4 for (a) unprotonated state, (b) protonated tautomer #1, and (c) protonated tautomer #2
shows that the physical end states are well sampled.
Table III
Sampling Characteristics of Three-State Titration Simulations Per-
formed at the pH Closest to the Model Compound’s pKa Value
Normal MD pH-REX
Residue pH FPS Transition (ns21) FPS Transition (ns21)
Asp-T 4 0.786 0.01 506 1 0.786 0.01 2946 16
Glu-T 4 0.766 0.01 466 7 0.756 0.00 3226 21
His-T 7 0.816 0.02 606 6 0.816 0.01 2986 12
Using pH-REX greatly accelerates sampling of titration coordinates with minimal
loss in the fraction of physical states (FPS).
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achieved by reducing the biasing potential at pH5 pKa
by kbTln(2)5 0.41 kcal/mol, which accounts for the
degeneracy of the tautomeric protonated states. Our
approach is different from that of Khandogin and
Brooks,62 where a post-correction factor of 0.3 pKa units
was applied to tautomeric residues. However, the net
result in both approaches is the same, in the sense that
the final pKa value calculated accounts for tautomer
degeneracy. The titration curves for our model com-
pounds with proton tautomerism are illustrated in Figure
3. The calculated pKa of aspartic and glutamic acid was
4.17 and 4.37 respectively, which is good agreement with
experimental pKa values. For histidine tautomeric titra-
tion, no re-calibration was performed because the pKa
measured by experiments were microscopic pKa associ-
ated with the titration at the Ne and Nd sites, and the
fixed biasing potential applied to each tautomer was
identical to those used in the 2-state titration setup. Our
calculated pKa for the histidine tautomer was 6.45, which
is identical to the expected macroscopic pKa value of
6.45.62
pKa calculations of proteins: Hen-egg white lysozyme
(HEWL)
The HEWL protein is a well-studied protein system that
contains the three most common titrating residues (Asp,
Glu, His) with microscopic pKa values for each residue that
have been measured in a number of experimental
studies.101–106 It is perhaps the closest thing to a
“universal benchmark” system that has been evaluated by
numerous CPHMD implementations over the
years.43,48,49,51,63,75,107 To the best of our knowledge, all
existing “pure” explicit solvent CPHMD simulations
reported in the literature have only been demonstrated on
small peptide compounds80 and simple organic mole-
cules.108 We performed a 20 ns pH-REX CPHMDMSkD sim-
ulation of HEWL, which is the first example of explicit
solvent CPHMD simulation on a full protein to be reported.
pKa calculations over 5 ns interval segments of our pH-
REX CPHMDMSkD trajectory show that good convergence
is achieved within 20 ns (Supporting Information Table
S3). The difference in pKa values across our triplicate runs
is small, typically between 0.2 and 0.3 pKa units, demon-
strating that our results are robust and reproducible. The
accuracy of our calculated pKa values are then compared
to experimental measurements from consensus NMR titra-
tions.106 As summarized in Table IV and Supporting
Information Figure S3, the calculated pKa values are in
good agreement with experiment, with a root-mean-
square-error (RMSE) of 0.85 pKa units and an average
unsigned error (AUE) of 0.68 pKa units. Webb et al. previ-
ously estimated that experimental pKa values reported in
the literature on average may vary by 0.5 pKa units depend-
ing on the experimental method and/or protocol used to
make the measurements.106 This suggests that the accuracy
of our pH-REX CPHMDMSkD simulations are approaching
the uncertainty of experimental pKa values. Next, we identi-
fied the residues that had errors in their calculated pKa val-
ues, which we defined as having more than 1.0 pKa unit
difference between calculated and experimental values. Asp-
119 was underpredicted by 21.9 pKa units, which suggests
that the unprotonated state is overstabilized in our simula-
tions. Analysis of its microenvironment indicates that per-
sistent hydrogen bond interactions between the carboxylic
oxygens of Asp-119 and the amide backbone hydrogen of
Gln-121 and Ala-122 were present even in a low pH envi-
ronment (Supporting Information Fig. S4), which accounts
for the extra stabilization of the unprotonated state of Asp-
119. Similar underprediction of Asp pKa values has been
documented in other CPHMD work, where salt bridge
interactions were responsible.49 When non-salt-bridge con-
figurations were sampled, it resulted in more accurate pKa
results.49 This suggests that the apparent error in the Asp-
119 pKa value could be a sampling issue, and more extensive
sampling or more aggressive sampling methods may be
required when dealing with residues that are “locked” to
their initial conformation by strong interactions like hydro-
gen bonds or salt bridges.
We compared the performance of explicit solvent pH-
REX CPHMDMSkD simulations to CPHMD models
implemented in other solvation models. A number of
Figure 3
Titration curve of model compounds with proton tautomerism: (a) aspartic acid, (b) glutamic acid, and (c) histidine. Calculated pKa values of
model compounds show excellent agreement with experimental pKa values. Colors represent the results from the triplicate runs.
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CPHMD variations have been implemented in AMBER48
and GROMACS.43 However, they will not be included
our analysis as deconvoluting the effects originating from
force field differences to those arising from solvation
model differences is not straightforward. Instead, we will
focus our analysis on CPHMD variations implemented
in CHARMM. The original CPHMD in CHARMM was
implemented with a GB implicit solvent model,61 and
we have used the HEWL pKa values reported by Wallace
and Shen for comparison.75 Since that work was
reported using a pH-REX sampling strategy, we have also
eliminated the effects of using different sampling strat-
egies. At the time of writing, there is no “pure” explicit
solvent CPHMD based on the CHARMM force field that
has been tested on the HEWL protein. However, a close
comparison can be made with Shen’s hybrid solvent
CPHMD model.75 The key methodological difference
between explicit and hybrid solvent models is that the
evaluation of free energies of deprotonation and the
forces on the fictitious k particles that govern the titra-
tion coordinates are calculated using a GB implicit sol-
vent model in Shen’s hybrid solvent CPHMD model,
whereas in our explicit solvent CPHMDMSkD model there
is no use of the GB implicit solvent model in any part of
the calculation. Unfortunately, the use of such hybrid
sampling means there is no clear Hamiltonian for this
system and correspondence to results from any specific
statistical mechanical approach cannot be demonstrated.
Lastly, the sampling of titration coordinates in implicit
solvent is typically 2000 transitions/ns,51 which is an
order of magnitude higher than those obtained in our
explicit solvent simulations. Therefore, to compensate for
the differential sampling speed associated with different
solvent models, we compared the results of our 20 ns
pH-REX CPHMDMSkD trajectories to the previously
reported 2 ns pH-REX trajectories that uses the implicit
and hybrid CPHMD model.
As summarized in Table IV, in terms of overall pKa
predictive performance, our explicit solvent
CPHMDMSkD results had a RMSE error of 0.84 pKa
units. This is an improvement from the results obtained
using implicit solvent CPHMD (RMSE5 0.94), and our
model performance is close to that of the hybrid solvent
CPHMD (RMSE5 0.80). A similar trend was also noted
using alternative error metrics, such as the average
unsigned error (AUE). We then identified the number of
residues that had errors of more than 1.0 pKa unit rela-
tive to experimental values. Our explicit solvent
CPHMDMSkD model had only 1 such residue (i.e., Asp-
119) compared to the implicit and hybrid solvent
CPHMD models which had five and three residues,
respectively. Notable improvements in moving from a
hybrid solvent to a “pure” explicit solvent model can be
observed in His-15, where the overestimation of its pKa
value is reduced from 1.1 to 0.5 pKa units. Similarly, the
hybrid solvent CPHMD model incorrectly predicted the
direction of pKa shift for residue Asp-101, whereas the
explicit solvent CPHMDMSkD model not only predicted
the right direction of pKa shift, but the magnitude of
error was also smaller (21.5 vs. 10.6). Our findings sug-
gest that when corrected for differences in titrating coor-
dinates sampling, the explicit solvent CPHMDMSkD
model produces more accurate pKa predictions than the
original implicit solvent CPHMD.
pKa calculations of proteins: Other proteins, BBL, and
NTL9
Lastly, to demonstrate that the pKa calculations
obtained from the CPHMDMSkD framework for proteins
is not specific to HEWL protein, we performed pKa cal-
culations on two additional proteins, the BBL and NTL9
protein. Given that we have only investigated a single
His residue in a protein environment, for BBL we only
Table IV
pKa Values of HEWL Calculated Using Implicit and Hybrid Solvent pH-REX CPHMD Simulations as Reported by Wallace and Shen,
75 Compared
with pKa Values Calculated Using Explicit Solvent pH-REX CPHMD
MSkD Simulations in this Work
Implicit CPHMD Hybrid CPHMD Explicit CPHMDMSkD
Residue Exp pKa pKa Error pKa Error pKa Error
GLU-7 2.66 0.2 2.66 0.1 0.0 2.76 0.0 0.1 2.76 0.1 0.1
HIS-15 5.56 0.2 5.36 0.5 20.2 6.66 0.1 1.1 6.06 0.2 0.5
ASP-18 2.86 0.3 2.96 0.0 0.1 3.16 0.1 0.3 2.16 0.2 20.7
GLU-35 6.16 0.4 4.46 0.2 21.8 7.26 0.2 1.1 7.06 0.3 0.9
ASP-48 1.46 0.2 2.86 0.2 1.4 1.66 0.5 0.2 1.36 0.0 20.1
ASP-52 3.66 0.3 4.66 0.0 1.0 2.96 0.1 20.7 4.56 0.3 0.9
ASP-66 1.26 0.2 1.26 0.4 20.1 1.56 0.6 0.3 1.56 0.1 0.3
ASP-87 2.26 0.1 2.06 0.1 20.2 1.56 0.4 20.7 1.36 0.0 20.9
ASP-101 4.56 0.1 3.36 0.3 21.2 3.06 0.1 21.5 5.16 0.5 0.6
ASP-119 3.56 0.3 2.56 0.1 21.1 2.96 0.1 20.7 1.66 0.0 21.9
RMSE 0.94 0.80 0.84
AUE 0.70 0.66 0.68
Calculated pKa values with error greater than 1.0 pKa unit relative to experimental values based on consensus NMR titrations
106 are identified in red.
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titrated the two His residues. NTL9 has no His residues,
and the Glu and Asp residues that have experimental
pKa measurements were titrated. As summarized in Table
V and Supporting Information Figure S5 the calculated
pKa values are reasonably accurate (RMSE5 0.72,
AUE5 0.59).109,110 From the experimental data, most
of the residues titrate close to the pKa of their reference
compounds, but two residues had more than a 1.0 pH
unit shift. For His-166 of BBL, the residue is buried and
its experimental pKa is 5.4. For Asp-8 of NTL9, its exper-
imental pKa of 3.0 can be traced to the salt bridge inter-
actions it forms with the amide backbone of adjacent
residues. Our calculated pKa values demonstrate a similar
downward shift, although in both cases the extent of the
shift tends to be overestimated. We suggest that this
overestimation may be due to the lack of sampling stem-
ming from the shorter 3 to 5 ns simulations performed
for these systems. In other proteins like staphylococcal
nuclease, residues with shifted pKa values are known to
undergo local conformational changes,26,28 and sam-
pling these states will be required to improve the accu-
racy of pKa calculations. Together with our observations
for Asp-119 in HEWL, our work suggests that while
short pH-REX CPHMDMSkD simulations are capable of
reproducing experimental pKa values of most protein res-
idues, accurate reproduction of highly shifted pKa values
(e.g., buried charged residues) or those involving salt-
bridge or similarly strong interactions remains a chal-
lenge that may be better addressed with more aggressive
conformational sampling techniques.
CONCLUSION
In conclusion, we have demonstrated the use of the
constant pH molecular dynamics framework based
on multi-site k-dynamics (CPHMDMSkD) to simulate
realistic pH-dependent properties of proteins. In the
CPHMDMSkD framework, we performed seamless
alchemical transitions between protonation and tauto-
meric states using multi-site k-dynamics, and designed a
novel biasing potential to ensure that only the physical
end-states are predominantly sampled. Then, we applied
explicit solvent CPHMDMSkD simulations to the proteins
HEWL, BBL and NTL9, which are the first examples of a
“pure” explicit solvent CPHMD on full protein systems
to be reported. Our pKa calculations for HEWL protein
are in excellent agreement with experimental values, with
a RMSE of 0.84 pKa units, and this is close to the uncer-
tainty of 0.50 pKa units associated with experimental
measurements. Our pKa calculations on the other model
protein systems, BBL and NTL9 also provide similarly
good agreement with experiments. In addition, compari-
son with implicit solvent CPHMD shows that explicit
solvent CPHMDMSkD produces results that are more
accurate, reducing the number of residues with large
errors in their pKa predictions from 5 to 1. With the
development of explicit solvent CPHMDMSkD for pro-
teins, it will finally allow us to confidently address ques-
tions related to pH-dependent properties of membrane
proteins and ion channels, where discrete representation
of ions and water is important. Coupled with the explicit
solvent CPHMDMSkD framework for nucleic acids, accu-
rate modeling of pH-dependent properties for all major
classes of biomolecules—proteins, nucleic acids, and even
protein-nucleic acid complexes is now a reality.
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